SAN FRANCISCO, CA – May 23, 2002 – The cytoprotective agent amifostine may reduce or prevent much of the damage in radiation-induced proctitis.
A Phase I dose escalation trial presented at Digestive Disease Week (DDW) found that the effect appeared to be dose related. Seven of 14 on the low dose had symptoms, but only two of the 13 who got the higher dose tested had symptoms of proctitis.
Dr. Nadeem Ullah, of the John Dingell VA medical center in Detroit, said that “this is a reduced rate from what is typically found in radiation therapy for prostate cancer.” Amifostine, a polyamine with antioxidant properties, is a cytoprotective agent.
It was well tolerated in the trial, and systemic effects from rectal application were negligible, Ullah said.
The trial studied 29 patients with localized prostate cancer, who received radiation doses of 70.2 Gy (20 patients) and 73.8 Gy (9 patients). The amifostine was applied into the rectum 30 minutes before the treatment sessions for the first 15 days of radiotherapy. Doses of
amifostine increased from 500 to 2500 mg by increments in the trial.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!